Tonix Pharmaceuticals (TNXP) vs Verrica Pharmaceuticals (VRCA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Verrica Pharmaceuticals (VRCA) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, losing 34.9% versus a loss of 85.2%. Over five years, VRCA leads with a -97.4% price change compared with -100.0% for TNXP. Verrica Pharmaceuticals is the larger company by market cap ($47.1 million vs $46.2 million), about 1.0 times the size.
Verrica Pharmaceuticals converts more of its revenue into profit, with a net margin of -50.3% versus -946.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TNXP | VRCA |
|---|---|---|
| Share price | $2.38 | $2.74 |
| Market cap | $46.25M | $47.07M |
| 1-day change | -6.67% | -5.03% |
| YTD return | -84.76% | -67.03% |
| 1-year return | -85.22% | -34.92% |
| 5-year return | -100.00% | -97.38% |
| EPS (TTM) | $-12.39 | $-2.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.11M | $35.58M |
| Revenue growth (YoY) | +29.85% | +370.22% |
| Net income (latest FY) | $-124.02M | $-17.89M |
| Gross margin | 49.34% | — |
| Operating margin | -959.05% | -34.25% |
| Net margin | -946.22% | -50.27% |
| 52-week high | $20.56 | $9.82 |
| 52-week low | $2.30 | $2.73 |
| Distance from 52-week high | -88.42% | -72.10% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1769.75% | +404.74% |
| Average volume | 838.83K | 68.78K |
| Shares outstanding | 19.43M | 17.18M |
| Employees | 142 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VRCA has outperformed TNXP by 50.3 percentage points over the past year.
- Verrica Pharmaceuticals is more profitable, keeping -50.3 cents of every revenue dollar as net income versus -946.2 cents for Tonix Pharmaceuticals.
- Verrica Pharmaceuticals grew revenue faster in its latest fiscal year (+370.22% vs +29.85%).
About Tonix Pharmaceuticals
TNXP stock →Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees
About Verrica Pharmaceuticals
VRCA stock →Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
TNXP vs VRCA FAQ
Which is bigger, Tonix Pharmaceuticals or Verrica Pharmaceuticals?
Verrica Pharmaceuticals (VRCA) is larger, with a market capitalization of $47.07M compared with $46.25M for Tonix Pharmaceuticals (TNXP).
Which stock has performed better over the past year, TNXP or VRCA?
VRCA returned -34.92% over the past 12 months, compared with -85.22% for TNXP (price return, excluding dividends). Past performance does not predict future results.
Are Tonix Pharmaceuticals and Verrica Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.